Influence of the cream with filaggrin activity modulator for dry and sensitive skin in children with mild to moderate severity atopic dermatitis on objective indicators of skin barrier function and disease severity indices

Abstract

BACKGROUND: Atopic dermatitis is a chronic, relapsing and severely itchy dermatitis that usually occurs in childhood and has a characteristic age-related distribution. Atopic dermatitis is relatively frequent, affecting 10–20% of children in developed countries. Atopic dermatitis in children associated with poor school performance, low self-esteem and family problems. Recent studies show importance in atopic dermatitis pathogenesis of protein filaggrin and modulation of its activity may be a promising direction in the pathogenic therapy of atopic dermatitis.

AIM: to study the effect of a cream for dry, sensitive and atopic skin with a modulator of filaggrin activity on the course of mild and moderate atopic dermatitis.

MATERIAL AND METHODS: An open, prospective, multicentre, non-comparative, single-group clinical trial was organized to test the effectiveness of a cream with a filaggrin activity modulator. The study was on outpatients in the participated centers and included 5 visits with a screening visit 1, and 5^th visit ― therapy completion. Cream was used for 12 weeks. In total, the study involved 60 children aged 3 to 18 years with diagnoses of atopic dermatitis of mild and moderate severity. The severity of atopic dermatitis was measured with the SCORAD, EASI, IGA scales, also measured was skin pH and transepidermal water loss (TEWL), as well as the severity of xerosis according to visual analogue scale.

RESULTS: The severity of atopic dermatitis in children whose therapy regimens included Admera cream decreased by 19.6 points according to the SCORAD index, including in children who did not receive mometasone furoate in the therapy schemes, the SCORAD index decreased statistically significantly compared to the baseline data (p <0.001). The overall decline in the EASI index ― by 3.0 points, the IGA global assessment index ― by 2.0 points, the severity of xerosis decreased by 3 points (in all cases, p <0.001). Transepidermal water loss decreased (by 4.5 g/m² per hour, p <0.001); Skin pH did not change (difference 0.02, p=0.34). The smell was rated as "excellent" by 86.7% (95% CI 75.4–94.1), the consistency ― by 83.3% (95% CI 71.5–91.7) of the respondents, and overall satisfaction was noted by ― 88.3% (95% CI 77.4–95.2) of the respondents.

CONCLUSION: Сream for dry and sensitive skin with a modulator of filaggrin activity during the study showed good efficacy and tolerability and can be used in atopic dermatitis treatment regimens as a basic care product, both during exacerbation and remission.

Keywords

atopic dermatitis / emollients / skin moisture / microbiome / SCORAD scale / TEWL measurements / filaggrin activity modulator

References

[1] Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci Rep. 2020;10(1):2721. doi: 10.1038/s41598-020-59627-7

[2] Smieszek S.P., Welsh S., Xiao C., et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status // Sci Rep. 2020. Vol. 10, N 1. Р. 2721. doi: 10.1038/s41598-020-59627-7

[3] Cepelak I, Dodig S, Pavic I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. doi: 10.11613/BM.2019.020501

[4] Cepelak I., Dodig S., Pavic I. Filaggrin and atopic march // Biochem Med (Zagreb). 2019. Vol. 29, N 2. Р. 020501. doi: 10.11613/BM.2019.020501

[5] Hoober JK, Eggink LL. The discovery and function of filaggrin. Int J Mol Sci. 2022;23(3):1455. doi: 10.3390/ijms23031455

[6] Hoober J.K., Eggink L.L. The discovery and function of filaggrin // Int J Mol Sci. 2022. Vol. 23, N 3. Р. 1455. doi: 10.3390/ijms23031455

[7] Marenholz I, Esparza-Gordillo J, Ruschendorf F, et al. Meta-analysis identifies seven susceptibility loci involved in the atopic march. Nat Commun. 2015;(6):8804. doi: 10.1038/ncomms9804

[8] Marenholz I., Esparza-Gordillo J., Ruschendorf F., et al. Meta-analysis identifies seven susceptibility loci involved in the atopic march // Nat Commun. 2015. Vol. 6. Р. 8804. doi: 10.1038/ncomms9804

[9] Dvornyk V, Ponomarenko I, Belyaeva T, et al. Filaggrin gene polymorphisms are associated with atopic dermatitis in women but not in men in the Caucasian population of Central Russia. PLoS One. 2021;16(12):e0261026. doi: 10.1371/journal.pone.0261026

[10] Dvornyk V., Ponomarenko I., Belyaeva T., et al. Filaggrin gene polymorphisms are associated with atopic dermatitis in women but not in men in the Caucasian population of Central Russia // PLoS One. 2021. Vol. 16, N 12. Р. e0261026. doi: 10.1371/journal.pone.0261026

[11] Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab. 2015;66 (Suppl 1):8–16. doi: 10.1159/000370220

[12] Nutten S. Atopic dermatitis: global epidemiology and risk factors // Ann Nutr Metab. 2015. Vol. 66, Suppl. 1. Р. 8–16. doi: 10.1159/000370220

[13] Zaslavsky DV, Barinova AN. Skin microbiome in atopic dermatitis and features of various basic skin care products. Medical council. 2018;(2):170–176. (In Russ). doi: 10.21518/2079-701X-2018-2-170-176

[14] Заславский Д.В., Баринова А.Н. Микробиом кожи при атопическом дерматите и особенности различных средств базисного ухода за кожей // Медицинский совет. 2018. № 2. С. 170–176. doi: 10.21518/2079-701X-2018-2-170-176

[15] Clausen ML, Agner T, Lilje B, et al. Association of disease severity with skin microbiome and filaggrin gene mutations in adult atopic dermatitis. JAMA Dermatol. 2018;154(3):293–300. doi: 10.1001/jamadermatol.2017.5440

[16] Clausen M.L., Agner T., Lilje B., et al. Association of disease severity with skin microbiome and filaggrin gene mutations in adult atopic dermatitis // JAMA Dermatol. 2018. Vol. 154, N 3. Р. 293–300. doi: 10.1001/jamadermatol.2017.5440

[17] O’Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122(4):689–693. doi: 10.1016/j.jaci.2008.08.002

[18] O’Regan G.M., Sandilands A., McLean W.H., Irvine A.D. Filaggrin in atopic dermatitis // J Allergy Clin Immunol. 2008. Vol. 122, N 4. Р. 689–693. doi: 10.1016/j.jaci.2008.08.002

[19] Strathie PS, Weston S, Loh R. Atopic dermatitis in children. Aust Fam Physician. 2016;45(5):293–296.

[20] Strathie P.S., Weston S., Loh R. Atopic dermatitis in children //Aust Fam Physician. 2016. Vol. 45, N 5. Р. 293–296.

[21] LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019;36(1):36–65. doi: 10.1111/pde.13678

[22] Le Poidevin L.M., Lee D.E., Shi V.Y. A comparison of international management guidelines for atopic dermatitis // Pediatr Dermatol. 2019. Vol. 36, N 1. Р. 36–65. doi: 10.1111/pde.13678

[23] Zaslavsky DV, Barinova AN. A new strategy of basic moisturizing therapy for atopic dermatitis — “emolents plus”. Dermatovenerology. Cosmetology. 2019;5(1):69–79. (In Russ).

[24] Заславский Д.В., Баринова А.Н. Новая стратегия базовой увлажняющей терапии при атопическом дерматите ― «эмоленты плюс» // Дерматовенерология. Косметология. 2019. Т. 5, № 1. С. 69–79.

[25] HanifIn JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl). 1980;(92):44–47. doi: 10.2340/00015555924447

[26] HanifIn J.M., Rajka G. Diagnostic features of atopic dermatitis // Acta Derm Venereol (Suppl). 1980. Vol. 92. Р. 44–47. doi: 10.2340/00015555924447

[27] Zaslavsky DV, Sobolev AV, Skrek SI, et al. Normalization of the epidermal barrier as a method of pathogenetic therapy of atopic dermatitis in children. Vestnik Dermatologii i venerologii. 2021;97(5):52–65. (In Russ). doi: 10.25208/vdv1255

[28] Заславский Д.В., Соболев А.В., Скрек С.В., и др. Нормализация эпидермального барьера как способ патогенетической терапии атопического дерматита у детей // Вестник дерматологии и венерологии. 2021. Т. 97, № 5. С. 52–65. doi: 10.25208/vdv1255

[29] Atopic dermatitis. Clinical recommendations. Moscow: The Russian Society of Dermatovenerologists and Cosmetologists, The Russian Association of Allergologists and Clinical Immunologists, The Union of Pediatricians of Russia; 2020. 81 р. (In Russ).

[30] Атопический дерматит. Клинические рекомендации. Москва: Российское общество дерматовенерологов и косметологов, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, 2020. 81 с.

[31] Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol. 2011;(41):149–155. doi: 10.1159/000323308

[32] Oranje A.P. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score // Curr Probl Dermatol. 2011. Vol. 41. Р. 149–155. doi: 10.1159/000323308

[33] Hanifin JM, Baghoomian W, Grinich E, et al. The eczema area and severity index--A practical guide. Dermatitis. 2022;33(3):187–192. doi: 10.1097/DER.0000000000000895

[34] Hanifin J.M., Baghoomian W., Grinich E., et al. The eczema area and severity index--A practical guide // Dermatitis. 2022. Vol. 33, N 3. Р. 187–192. doi: 10.1097/DER.0000000000000895

Funding

ООО «Др. Редди’с Лабораторис»Dr. Reddy’s Lab

RIGHTS & PERMISSIONS

Eco-Vector